Fortress Biotech - FBIO Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FBIO shares.
View FBIO analyst ratings or view top-rated stocks.

4 analysts have issued 1 year price targets for Fortress Biotech's shares. Their FBIO share price forecasts range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 623.9% from the stock's current price.
View analysts price targets for FBIO or view top-rated stocks among Wall Street analysts.

Fortress Biotech's stock was trading at $0.6550 on January 1st, 2023. Since then, FBIO stock has increased by 26.5% and is now trading at $0.8289.
View the best growth stocks for 2023 here.

Fortress Biotech saw a decline in short interest in January. As of January 15th, there was short interest totaling 391,700 shares, a decline of 51.3% from the December 31st total of 804,100 shares. Based on an average daily trading volume, of 395,800 shares, the short-interest ratio is presently 1.0 days. Approximately 0.5% of the shares of the stock are sold short.
View Fortress Biotech's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our FBIO earnings forecast.

Fortress Biotech, Inc. (NASDAQ:FBIO) posted its quarterly earnings results on Monday, November, 14th. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.02. The biopharmaceutical company earned $16.53 million during the quarter, compared to analysts' expectations of $19.02 million. Fortress Biotech had a negative net margin of 117.49% and a negative trailing twelve-month return on equity of 54.56%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Fortress Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (0.76%), 1900 Wealth Management LLC (0.12%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eric K Rowinsky, Lindsay A Md Rosenwald, Malcolm Hoenlein and Robyn Hunter.
View institutional ownership trends.

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FBIO stock can currently be purchased for approximately $0.83.

Fortress Biotech (NASDAQ:FBIO) has a market capitalization of $89.31 million and generates $68.79 million in revenue each year. The biopharmaceutical company earns $-64,700,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

The company employs 173 workers across the globe.

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.fortressbiotech.com. The biopharmaceutical company can be reached via phone at (781) 652-4500, via email at ir@fortressbiotech.com, or via fax at 781-652-4545.